Intermediate and high-risk localised, completely resected, gastrointestinal stromal tumours (GIST) expressing KIT receptor: a controlled randomised trial of adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery.

 

Trial Summary:

Imatinib mesylate is highly effective for advanced, unresectable gastrointestinal stromal tumours. However, its long-term effect on survival outcomes remains unclear. This study will compare the effect of adjuvant imatinib mesylate versus observation only on the prognosis of patients with completely resected localised gastrointestinal stromal tumours at intermediate or high risk of relapse.

Supported By:

Novartis Pharmaceuticals Australia; AGITG

Eligibility:

Patients with intermediate- and high-risk localised, completely resected, gastrointestinal stromal tumours.

Registration ID:

ACTRN12605000712606

Participation:

International

Australian Lead Group:

AGITG

Status:

Close out

Activation Date:

04/11/2005

Chairs:

Dusan Kotesek (ANZ study chair)

Contact:

adjGIST.study@sydney.edu.au